This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Gains from Focus on Coronavirus Treatments
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
6 Top-Ranked S&P 500 Stocks Ride Out the Coronavirus Rout
by Aniruddha Ganguly
Here we discuss six S&P 500 stocks that are in the black despite the coronavirus scare.
5 Drug Makers to Gain From Coronavirus Outbreak
by Zacks Equity Research
Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.
The Zacks Analyst Blog Highlights: Co-Diagnostics, Regeneron Pharmaceuticals, Netflix, Norwegian Cruise Line and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, Regeneron Pharmaceuticals, Netflix, Norwegian Cruise Line and American Airlines
Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
by Kinjel Shah
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
Best & Worst Performing Stocks in Coronavirus Outbreak
by Tirthankar Chakraborty
Here're the big winners and losers since the coronavirus outbreak brought the U.S. bull market to a standstill.
MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
by Zacks Equity Research
MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.
Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength
by Zacks Equity Research
Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.
Immunomedics (IMMU) Reports Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected Q4 loss. Its BLA seeking accelerated approval for sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) is accepted for filing by FDA.
Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat
by Zacks Equity Research
Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.
Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates
by Zacks Equity Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.
ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.
Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.
Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings
by Zacks Equity Research
Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.
Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.
Will Regeneron Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Regeneron Pharmaceuticals.
Sanofi Plans Spin-Off of API Unit Into a European Company
by Zacks Equity Research
Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.
Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected loss and misses revenue estimates in fourth-quarter 2019. Shares down.
Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.
Regeneron (REGN) Catches Eye: Stock Jumps 5.5%
by Zacks Equity Research
Regeneron (REGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.